Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial

News
Video
Conference|ASCO Annual Meeting: Genitourinary

This video reviews second-line data from the IMmotion150 trial, which initially studied atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients.

Michael B. Atkins, MD, on Atezolizumab/Bevacizumab in Metastatic RCC
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Michael B. Atkins, MD, of Georgetown University in Washington, DC, discusses second-line data from the IMmotion150 trial.

      The study initially tested first-line atezolizumab vs sunitinib vs atezolizumab plus bevacizumab in untreated patients with metastatic renal cell carcinoma, and demonstrated an improved progression-free survival for the atezolizumab/bevacizumab combination.

      Atkins presented second-line results of the study (abstract 4505) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

      Recent Videos
      Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
      Incentivizing RCC Research Investment Across Lower-Income Countries
      Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
      EV-302 Trial Shows ‘Impressive’ Data in Bladder Cancer Responder Population
      Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
      Identifying Regional Kidney Cancer Needs Via International Collaboration
      Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
      Using Biopsies to Inform Response Characteristics in Kidney Cancer
      Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
      Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
      Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
      Kidney Cancer Research Consortium Efforts May Improve Treatment Outcomes
      An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
      Kidney Cancer Research Program May Play Pivotal Role in Advancing Care
      Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
      Connecting With Congress to Advance Kidney Cancer Research
      Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
      Collaboration and Research Funding Advancements in Kidney Cancer Advocacy
      A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
      Radiologic Assessment May Be Used Before First Line Therapy for mccRCC
      Related Content
      Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

      Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

      Tim Cortese
      March 19th 2025
      Article

      Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
      March 7th 2025
      Podcast

      A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

      Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

      Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

      Russ Conroy
      February 26th 2025
      Article

      Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

      Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

      Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

      Eric Jonasch, MD
      February 3rd 2025
      Podcast

      Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

      PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC

      PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC

      Ashley Chan
      February 16th 2025
      Article

      The TiNivo-2 trial found comparable PROs with tivozanib plus nivolumab vs tivozanib monotherapy in advanced clear cell RCC.

      Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

      Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

      Ariana Pelosci
      February 15th 2025
      Article

      Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.